The U.S. Food and Drug Administration (FDA) is facing internal disagreements over the accessibility of pediatric Covid-19 vaccines. While agency staff scientists have raised concerns about the unpredictable nature of the virus and its potential threat to toddlers, an FDA official has opted to limit vaccine access to children with specific risk factors. This decision contradicts the recommendations of Dr. Vinay Prasad, a medical professional who advocates for narrowing vaccine approvals to individuals under 65 years of age with health conditions that elevate their risk of severe illness from Covid-19. The situation underscores the complex dynamics within regulatory agencies and the potential impacts of policy decisions on public health strategies.